My watch list
my.bionity.com  

my.bionity.com

With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Pertuzumab



Pertuzumab?
Therapeutic monoclonal antibody
Source Human
Target HER2
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Pertuzumab (also called 2C4, formerly known as Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[1] Omnitarg is currently being developed by Genentech.

Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[2]

References

[1]

  1. ^ a b de Bono, Johann S. (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology 25 (3): 257-262.
  2. ^ Genentech press release - May 15, 2005
v • d • e
Humanized monoclonal antibodies
CancerAlemtuzumab, Apolizumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab
ImmunosuppressionAselizumab, Atlizumab, Cedelizumab, Daclizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab
Viral infectionsFelvizumab, Palivizumab, PRO 140
otherBapineuzumab, Certolizumab pegol, Eculizumab, Motavizumab, Natalizumab, Ocrelizumab, Omalizumab, Ranibizumab, Tadocizumab, Tefibazumab, Tucotuzumab celmoleukin, Urtoxazumab
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pertuzumab". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE